Immuneering Corp (IMRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.56
- As of
Kresmion compiles this page from IMRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Immuneering Corp (IMRX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
See the full IMRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IMRX on one page. Preview it with sample data, then open it live with a free account.
Preview the IMRX dossierActive signals for IMRX
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +271% to IMRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +342% to IMRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2228% to IMRX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 70% of IMRX (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in IMRX
FREE, NO ACCOUNT
Every signal on IMRX, as it fires
You are seeing 5 of 11 signals recorded on IMRX since 2026-05-27.
The five above all landed on 2026-08-16. The other 6 were recorded on 3 other days. 7 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IMRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 45254E107 · 2026Q2 | $1.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45254E107 · 2026Q2 | $1.6M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45254E107 · 2026Q2 | $1.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 45254E107 · 2026Q2 | $1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IMRX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IMRX mentioned in Kresmion daily briefs
IMRX against its peers
IMRX's return on equity of -25.6% ranks in the 73rd percentile of 23 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | IMRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 14.6M | n/a | 17 |
| Operating margin | n/a | -251.6% | n/a | 15 |
| Net margin | n/a | -369.1% | n/a | 16 |
| Return on equity | -25.6% | -42.2% | 73 | 23 |
| 1 year | -42.0% | 8.0% | 33 | 19 |
Peers (24): LCTX, LXEO, KROS, LRMR, UPB, FATE, GLSI, SLGL, ZNTL, SABS, ACIU, SION, STRO, IFRX, QTTB, CAMP, PYXS, EVMN, MGNX, IKT, PLX, RCKT, IPSC, BCYC. Left out: VCRE (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (IMRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IMRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IMRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.